1
|
Brooks MB, Brooks JC, Catalfamo J, Zhu Y, Goggs R, Babasyan S, Wagner B, LeVine DN. Plasma concentration of thrombopoietin in dogs with immune thrombocytopenia. J Vet Intern Med 2024. [PMID: 39143652 DOI: 10.1111/jvim.17152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Accepted: 07/16/2024] [Indexed: 08/16/2024] Open
Abstract
BACKGROUND Immune thrombocytopenia (ITP) is a common cause of severe thrombocytopenia in dogs. The pathogenesis of nonassociative, primary ITP (pITP) appears complex, with ill-defined thrombopoietic response. OBJECTIVES Develop an immunoassay to measure plasma canine thrombopoietin (TPO) concentration and characterize TPO concentrations in dogs with pITP. ANIMALS Forty-one healthy dogs, 8 dogs in an induced ITP model (3 control, 5 ITP), and 58 pITP dogs. METHODS Recombinant canine TPO (rcTPO) was purchased and its identity confirmed by mass spectrometry. Monoclonal antibodies were raised to rcTPO and used to configure a sandwich ELISA using streptavidin-biotin detection. Assay performance, coefficients of variability, and healthy dog plasma TPO reference interval (RI) were determined, followed by assay of ITP samples. RESULTS Assay dynamic range was 15 pg/mL (lower limit of detection) to 1000 pg/mL TPO, with limit of quantitation of 62 pg/mL. Plasma TPO RI was 0 to 158 pg/mL, with plasma TPO <62 pg/mL for 35/41 healthy dogs. All dogs with induced ITP developed marked increases in plasma TPO concentration. Peak values ranged from 515 to >6000 pg/mL. In contrast, only 2/58 pITP dogs had TPO values above RI. CONCLUSIONS AND CLINICAL IMPORTANCE Plasma TPO concentration is paradoxically low at diagnosis for most dogs with pITP. This finding suggests that ineffective thrombopoiesis contributes to thrombocytopenia in pITP dogs and supports evaluating TPO receptor agonist treatment as used for pITP in humans. The TPO assay provides a new tool to study thrombopoiesis in pITP and other thrombocytopenic syndromes in dogs.
Collapse
Affiliation(s)
- Marjory B Brooks
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - James C Brooks
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Jim Catalfamo
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Yao Zhu
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Robert Goggs
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Susanna Babasyan
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Bettina Wagner
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Dana N LeVine
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
| |
Collapse
|
2
|
Zoia A, Busato F, Drigo M. Retrospective evaluation of the short-term response of human intravenous immunoglobulin therapy in the management of canine immune-mediated thrombocytopenia (2010-2015): 27 cases. J Vet Emerg Crit Care (San Antonio) 2024. [PMID: 39037266 DOI: 10.1111/vec.13408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2022] [Revised: 05/05/2023] [Accepted: 06/25/2023] [Indexed: 07/23/2024]
Abstract
OBJECTIVE To describe the short-term response, early prognostic markers, and survival after treatment of canine immune-mediated thrombocytopenia (ITP) with human intravenous immunoglobulin (hIVIG) and methylprednisolone. DESIGN Retrospective cohort study. SETTINGS Private referral veterinary medical center. ANIMALS Twenty-seven client-owned dogs with primary or secondary ITP. INTERVENTIONS All dogs received 2 mg/kg IV methylprednisolone once daily and a single infusion of 5% hIVIG administered over 6-12 hours. MEASUREMENTS AND MAIN RESULTS A substantial increase in platelet count within 60 ± 12 hours post-hIVIG infusion (T60) was observed in 19 of the 27 (70%) dogs with ITP (responders). Thirty-four variables, including serum immunoglobulin (Ig) G concentration 24 ± 12 hours post-hIVIG infusion (T24IgG) and increase in serum IgG concentration 24 ± 12 hours post-hIVIG infusion (T24ΔIgG), were compared between responders and nonresponders at 5 different time points. Mortality rates of responders and nonresponders were evaluated 14 days post-hIVIG infusion. Serum T24IgG and serum T24ΔIgG were both significantly higher at T60 in responders. All responders were alive 14 days post-hIVIG infusion, and their mortality rate was significantly lower compared with nonresponders. CONCLUSIONS Responder dogs had an excellent 14-day survival rate. Serum T24IgG and serum T24ΔIgG concentrations accurately predicted response status at 60 hours post-hIVIG infusion.
Collapse
Affiliation(s)
- Andrea Zoia
- Division of Internal Medicine, San Marco Veterinary Clinic, Veggiano, Italy
| | - Francesca Busato
- Division of Internal Medicine, San Marco Veterinary Clinic, Veggiano, Italy
| | - Michele Drigo
- Department of Medicina Animale, Produzione e Salute, Padua University, Legnaro, Italy
| |
Collapse
|
3
|
LeVine DN, Goggs R, Kohn B, Mackin AJ, Kidd L, Garden OA, Brooks MB, Eldermire ERB, Abrams‐Ogg A, Appleman EH, Archer TM, Bianco D, Blois SL, Brainard BM, Callan MB, Fellman CL, Haines JM, Hale AS, Huang AA, Lucy JM, O'Marra SK, Rozanski EA, Thomason JM, Walton JE, Wilson HE. ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats. J Vet Intern Med 2024; 38:1982-2007. [PMID: 38779941 PMCID: PMC11256181 DOI: 10.1111/jvim.17079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2024] [Accepted: 04/04/2024] [Indexed: 05/25/2024] Open
Abstract
Management of immune thrombocytopenia (ITP) in dogs and cats is evolving, but there are no evidence-based guidelines to assist clinicians with treatment decisions. Likewise, the overall goals for treatment of ITP have not been established. Immunosuppressive doses of glucocorticoids are the first line treatment, but optimal treatment regimens beyond glucocorticoids remain uncertain. Additional options include secondary immunosuppressive drugs such as azathioprine, modified cyclosporine, and mycophenolate mofetil, usually selected based on clinician preference. Vincristine, human IV immunoglobulin (hIVIg), and transfusion of platelet or red blood cell-containing products are often used in more severe cases. Splenectomy and thrombopoietin receptor agonists are usually reserved for refractory cases, but when and in which patient these modalities should be employed is under debate. To develop evidence-based guidelines for individualized treatment of ITP patients, we asked 20 Population Intervention Comparison Outcome (PICO) format questions. These were addressed by 17 evidence evaluators using a literature pool of 288 articles identified by a structured search strategy. Evidence evaluators, using panel-designed templates and data extraction tools, summarized evidence and created guideline recommendations. These were integrated by treatment domain chairs and then refined by iterative Delphi survey review to reach consensus on the final guidelines. In addition, 19 non-PICO questions covering scenarios in which evidence was lacking or of low quality were answered by expert opinion using iterative Delphi surveys with panelist integration and refinement. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The rigorous consensus process identified few comparative treatment studies, highlighting many areas of ITP treatment requiring additional studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Diagnosis of Immune Thrombocytopenia in Dogs and Cats.
Collapse
Affiliation(s)
- Dana N. LeVine
- Department of Clinical Sciences, College of Veterinary MedicineAuburn UniversityAuburnAlabamaUSA
| | - Robert Goggs
- Department of Clinical Sciences, College of Veterinary MedicineCornell UniversityIthacaNew YorkUSA
| | - Barbara Kohn
- Small Animal Clinic, School of Veterinary MedicineFreie Universität BerlinBerlinGermany
| | - Andrew J. Mackin
- Department of Clinical Sciences, College of Veterinary MedicineMississippi State UniversityMississippi StateMississippiUSA
| | - Linda Kidd
- Linda Kidd Veterinary Internal Medicine ConsultingCarlsbadCaliforniaUSA
| | - Oliver A. Garden
- School of Veterinary MedicineLouisiana State UniversityBaton RougeLouisianaUSA
| | - Marjory B. Brooks
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary MedicineCornell UniversityIthacaNew YorkUSA
| | - Erin R. B. Eldermire
- Flower‐Sprecher Veterinary Library, College of Veterinary MedicineCornell UniversityIthacaNew YorkUSA
| | - Anthony Abrams‐Ogg
- Department of Clinical Studies, Ontario Veterinary CollegeUniversity of GuelphGuelphOntarioCanada
| | | | | | - Domenico Bianco
- College of Veterinary MedicineWestern University of Health SciencesPomonaCaliforniaUSA
| | - Shauna L. Blois
- Department of Clinical Studies, Ontario Veterinary CollegeUniversity of GuelphGuelphOntarioCanada
| | - Benjamin M. Brainard
- Department of Small Animal Medicine and Surgery, College of Veterinary MedicineUniversity of GeorgiaAthensGeorgiaUSA
| | - Mary Beth Callan
- Department of Clinical Sciences and Advanced Medicine, School of Veterinary MedicineUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
| | - Claire L. Fellman
- Department of Clinical Sciences, Cummings School of Veterinary MedicineTufts UniversityNorth GraftonMassachusettsUSA
| | - Jillian M. Haines
- Department of Veterinary Clinical Sciences, College of Veterinary MedicineWashington State UniversityPullmanWashingtonUSA
| | | | | | | | - Shana K. O'Marra
- Northwest Veterinary Critical Care ServicesVancouverWashingtonUSA
| | - Elizabeth A. Rozanski
- Department of Clinical Sciences, Cummings School of Veterinary MedicineTufts UniversityNorth GraftonMassachusettsUSA
| | - John M. Thomason
- Department of Clinical Sciences, College of Veterinary MedicineMississippi State UniversityMississippi StateMississippiUSA
| | - Jenny E. Walton
- Veterinary Apheresis Service UKWashingtonTyne and WearUnited Kingdom
| | - Helen E. Wilson
- Langford VetsUniversity of BristolLangfordSomersetUnited Kingdom
| |
Collapse
|
4
|
LeVine DN, Kidd L, Garden OA, Brooks MB, Goggs R, Kohn B, Mackin AJ, Eldermire ERB, Chang Y, Allen J, Christopherson PW, Glanemann B, Maruyama H, Naskou MC, Nielsen LN, Shropshire S, Viall AK, Birkenheuer AJ, Forman MA, Hanzlicek AS, Langner KF, Lashnits E, Lunn KF, Makielski KM, Roura X, Spada E. ACVIM consensus statement on the diagnosis of immune thrombocytopenia in dogs and cats. J Vet Intern Med 2024; 38:1958-1981. [PMID: 38752421 PMCID: PMC11256148 DOI: 10.1111/jvim.16996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Accepted: 01/16/2024] [Indexed: 07/19/2024] Open
Abstract
Immune thrombocytopenia (ITP) is the most common acquired primary hemostatic disorder in dogs. Immune thrombocytopenia less commonly affects cats but is an important cause of mortality and treatment-associated morbidity in both species. Immune thrombocytopenia remains a diagnosis of exclusion for which diagnostic guidelines are lacking. Primary, or non-associative, ITP refers to autoimmune platelet destruction. Secondary, or associative, ITP arises in response to an underlying disease trigger. However, evidence for which comorbidities serve as ITP triggers has not been systematically evaluated. To identify key diagnostic steps for ITP and important comorbidities associated with secondary ITP, we developed 12 Population Evaluation/Exposure Comparison Outcome (PECO) format questions. These questions were addressed by evidence evaluators utilizing a literature pool of 287 articles identified by the panelists using a structured search strategy. Evidence evaluators, using panel-designed templates and data extraction tools, summarized evidence and created guideline recommendations that then were integrated by diagnosis and comorbidity domain chairs. The revised PECO responses underwent a Delphi survey process to reach consensus on final guidelines. A combination of panel expertise and PECO responses were employed to develop algorithms for diagnosis of ITP in dogs and cats, which also underwent 4 iterations of Delphi review. Comorbidity evidence evaluators employed an integrated measure of evidence (IME) tool to determine evidence quality for each comorbidity; IME values combined with evidence summaries for each comorbidity were integrated to develop ITP screening recommendations, which also were subjected to Delphi review. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The final consensus statement provides clinical guidelines for the diagnosis of, and underlying disease screening for, ITP in dogs and cats. The systematic consensus process identified numerous knowledge gaps that should guide future studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Treatment of Immune Thrombocytopenia.
Collapse
Affiliation(s)
- Dana N. LeVine
- Department of Clinical Sciences, College of Veterinary MedicineAuburn UniversityAuburnAlabamaUSA
| | - Linda Kidd
- Western University of Health Sciences College of Veterinary MedicinePomonaCaliforniaUSA
- Zoetis Animal Health DiagnosticsParsippanyNew JerseyUSA
| | - Oliver A. Garden
- School of Veterinary MedicineLouisiana State UniversityBaton RougeLouisianaUSA
| | - Marjory B. Brooks
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary MedicineCornell UniversityIthacaNew YorkUSA
| | - Robert Goggs
- Department of Clinical Sciences, College of Veterinary MedicineCornell UniversityIthacaNew YorkUSA
| | - Barbara Kohn
- Clinic for Small Animals, Faculty of Veterinary Medicine, Freie Universität BerlinBerlinGermany
| | - Andrew J. Mackin
- College of Veterinary MedicineMississippi State UniversityStarkvilleMississippiUSA
| | - Erin R. B. Eldermire
- Flower‐Sprecher Veterinary Library, College of Veterinary MedicineCornell UniversityIthacaNew YorkUSA
| | - Yu‐Mei Chang
- Department of Comparative Biomedical SciencesRoyal Veterinary CollegeLondonUK
| | - Julie Allen
- Veterinary Information NetworkDavisCaliforniaUSA
| | | | - Barbara Glanemann
- Department of Clinical Science and Services, Royal Veterinary CollegeUniversity of LondonLondonUK
| | - Haruhiko Maruyama
- Department of Veterinary Medicine, College of Bioresource SciencesNihon UniversityChiyoda CityJapan
| | - Maria C. Naskou
- Department of Pathobiology, College of Veterinary MedicineAuburn UniversityAuburnAlabamaUSA
| | - Lise N. Nielsen
- Department of Veterinary Clinical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Sarah Shropshire
- College of Veterinary Medicine and Biomedical SciencesColorado State UniversityFort CollinsColoradoUSA
| | - Austin K. Viall
- Department of Pathology, Microbiology, and ImmunologySchool of Veterinary Medicine, University of California, DavisDavisCaliforniaUSA
| | - Adam J. Birkenheuer
- College of Veterinary MedicineNorth Carolina State UniversityRaleighNorth CarolinaUSA
| | | | | | | | - Erin Lashnits
- School of Veterinary MedicineUniversity of WisconsinMadisonWisconsinUSA
| | | | - Kelly M. Makielski
- College of Veterinary MedicineUniversity of MinnesotaSt PaulMinnesotaUSA
| | - Xavier Roura
- Hospital Clinic Veterinari, Universitat Autonoma de BarcelonaBellaterraSpain
| | - Eva Spada
- Veterinary Transfusion Research Laboratory (REVLab), Department of Veterinary Medicine and Animal SciencesUniversity of MilanLodiItaly
| |
Collapse
|
5
|
Ryu M, Kim J, An J, Seo K, Oh Y, Youn H. Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes. J Vet Intern Med 2024; 38:2158-2164. [PMID: 39023218 PMCID: PMC11256157 DOI: 10.1111/jvim.17131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 05/31/2024] [Indexed: 07/20/2024] Open
Abstract
BACKGROUND Romiplostim, a thrombopoietin analog, is commonly used to treat immune-mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited. OBJECTIVES Evaluate the effects and adverse events of romiplostim administration in dogs with thrombocytopenia caused by various underlying diseases. ANIMALS Forty-two client-owned dogs with naturally occurring thrombocytopenia at 2 referral animal hospitals. METHODS Retrospective, multi-institutional analysis to evaluate the outcomes of romiplostim treatment in dogs. RESULTS Among the dogs treated with romiplostim, 27 experienced an increase in platelet count and 26 maintained a platelet count within the reference range. Platelet count improvement was observed in various conditions: primary ITP (90%, n = 18/20), pancytopenia of unknown etiology (42.9%, n = 3/7), chemotherapy-induced thrombocytopenia (50%, n = 3/6), babesiosis (100%, n = 1/1), radiotherapy-induced thrombocytopenia (0%, n = 0/1), and disseminated intravascular coagulopathy (33.3%, n = 2/6). The median time for platelet recovery (>50 000/μL) after romiplostim administration was 4 days, and the median time for platelet count normalization was 7 days. Median hospitalization time for the improvement group (I) was 5 days. The survival-to-discharge rates were 85%, 40%, and 28.6% for dogs with primary ITP, secondary thrombocytopenia, and thrombocytopenia of unknown etiology, respectively. CONCLUSIONS AND CLINICAL IMPORTANCE Romiplostim is a well-tolerated and promising treatment for primary ITP in dogs, suggesting its potential as a valuable therapeutic option for dogs with thrombocytopenia caused by various underlying conditions. These findings emphasize the need for further research to optimize romiplostim dosing and understand its role in treating secondary thrombocytopenia and pancytopenia of unknown etiology.
Collapse
Affiliation(s)
- Min‐Ok Ryu
- Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science and Research Institute for Veterinary ScienceSeoul National UniversitySeoul 08826Republic of Korea
| | - Jin‐Kyung Kim
- Haemaru Companion Animal Medical FoundationSeongnamRepublic of Korea
| | - Ju‐Hyun An
- Department of Veterinary Emergency and Critical Care Medicine and Institute of Veterinary Science, College of Veterinary MedicineKangwon National UniversityChuncheon‐siRepublic of Korea
| | - Kyoung‐Won Seo
- Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science and Research Institute for Veterinary ScienceSeoul National UniversitySeoul 08826Republic of Korea
| | - Ye‐In Oh
- Department of Veterinary Internal Medicine, College of Veterinary Medicine & Institute for Veterinary Biomedical ScienceKyungpook National University, Daehakro 80DaeguRepublic of Korea
| | - Hwa‐Young Youn
- Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science and Research Institute for Veterinary ScienceSeoul National UniversitySeoul 08826Republic of Korea
| |
Collapse
|
6
|
Aspinall S, Desmas I, Bazelle J. Use of eltrombopag and granulocyte colony‐stimulating factor in treatment of lomustine overdose in a dog. VETERINARY RECORD CASE REPORTS 2021. [DOI: 10.1002/vrc2.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
7
|
Polydoros T, Ioannidi OM, Korsavvidis I, Stefanidis S, Antoniadis T, Mylonakis ME. Romiplostim as Adjunctive Treatment of Refractory Amegakaryocytic Immune Thrombocytopenia in a Dog. Top Companion Anim Med 2020; 42:100488. [PMID: 33115689 DOI: 10.1016/j.tcam.2020.100488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 09/15/2020] [Accepted: 09/28/2020] [Indexed: 11/19/2022]
Abstract
A 9-year-old, intact male, mixed-breed dog was admitted with a 3-day history of severe thrombocytopenia and bleeding diathesis. Physical examination revealed mucosal and cutaneous petechiae and ecchymoses, melena, and gross hematuria. Clinicopathologic evaluation indicated severe thrombocytopenia, anemia, and panhypoproteinemia. Serology for common endemic vector-borne pathogens was negative and thoracic and abdominal imaging was unremarkable. Bone marrow aspiration cytology revealed aplasia of the megakaryocytic lineage, in the context of a mildly hypoplastic myeloid and a normal erythroid series. A diagnosis of presumptive primary amegakaryocytic immune thrombocytopenia (ITP) was established. Treatment with vincristine, prednisolone, and mycophenolate mofetil along with several whole blood transfusions failed to achieve clinical and clinicopathologic remission. As an adjunct treatment, romiplostim was administered at a cumulative dose of 15 μg/kg, subcutaneously, in 2 sessions, 1 week apart, and complete clinical and hematological remission was noted 8 days postinitiation of romiplostim. Thirty-eight months later, the dog remains clinically healthy with no evidence of hematological relapse. Romiplostim could be a promising adjunctive treatment option in dogs with refractory ITP.
Collapse
Affiliation(s)
- Thomas Polydoros
- Companion Animal Clinic, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Olympia M Ioannidi
- Companion Animal Clinic, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | | | | | - Theocharis Antoniadis
- Diagnostic Laboratory, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Mathios E Mylonakis
- Companion Animal Clinic, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
| |
Collapse
|
8
|
Robin E, Le Boedec K. Pathology in Practice. J Am Vet Med Assoc 2020; 256:179-182. [PMID: 31910086 DOI: 10.2460/javma.256.2.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
9
|
Whitley N. Dealing with immune‐mediated haematological diseases in dogs and cats 2. Thrombocytopenia and Evan's syndrome. IN PRACTICE 2020. [DOI: 10.1136/inp.l6458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
10
|
Lee JS, Bellis TJ, Yoskowitz AS, Levitin B. "Acute onset tetraplegia associated with immune-mediated thrombocytopenia and suspected secondary intraspinal hemorrhage in a dog". Clin Case Rep 2019; 7:1673-1679. [PMID: 31534725 PMCID: PMC6745400 DOI: 10.1002/ccr3.2295] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 06/07/2019] [Accepted: 06/10/2019] [Indexed: 01/12/2023] Open
Abstract
Neurologic manifestations of immune-mediated thrombocytopenia are uncommon, and limited reports exist in human and veterinary medicine. This report documents acute onset of tetraplegia in a dog with immune-mediated thrombocytopenia and suspected secondary intraspinal hemorrhage with subsequent recovery of neurologic function following treatment.
Collapse
Affiliation(s)
- Jasmine S. Lee
- Emergency and Critical CareBluePearl Veterinary PartnersNew YorkNew York
| | - Tara Jane Bellis
- Emergency and Critical CareBluePearl Veterinary PartnersNew YorkNew York
| | | | - Boaz Levitin
- NeurologyBluePearl Veterinary PartnersNew YorkNew York
| |
Collapse
|
11
|
Kohn B, Bal G, Chirek A, Rehbein S, Salama A. Erratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim. BMC Vet Res 2016; 12:290. [PMID: 28038671 PMCID: PMC5200968 DOI: 10.1186/s12917-016-0787-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Accepted: 07/27/2016] [Indexed: 05/29/2023] Open
Affiliation(s)
- Barbara Kohn
- Small Animal Clinic, Veterinary Medicine at the Freie Universität Berlin, Oertzenweg 19b, Berlin, 14163, Germany
| | - Gürkan Bal
- Institute of Transfusion Medicine, Charité - Universitätsklinikum Berlin, Augustenburger Platz 1, Berlin, 13353, Germany
| | - Aleksandra Chirek
- Small Animal Clinic, Veterinary Medicine at the Freie Universität Berlin, Oertzenweg 19b, Berlin, 14163, Germany
| | - Sina Rehbein
- Small Animal Clinic, Veterinary Medicine at the Freie Universität Berlin, Oertzenweg 19b, Berlin, 14163, Germany
| | - Abdulgabar Salama
- Institute of Transfusion Medicine, Charité - Universitätsklinikum Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
| |
Collapse
|